Myasthenia Gravis
Basics
Basics
Basics
Description
Description
- Autoimmune antibody–mediated condition that results in painless, fatigable skeletal muscle weakness
 - Ocular or generalized:
- Ocular (eyelids and extraocular) muscle weakness:
- Most common initial symptom (60%)
 - ∼80% of myasthenia gravis (MG) patients who present with ocular weakness initially will progress to general weakness within 2 yr
 
 - Generalized:
- Usually affects proximal limbs, axial muscle groups such as neck, face, bulbar muscles
 
 
 - Acute or subacute, with relapses and remissions
 - Associated with thymoma in 10–15% and thymic hyperplasia in 60–70%
 - Myasthenic crisis:
- Respiratory failure or inability to protect airway due to weakness
 - Triggers:
- Infection
 - Surgery
 - Trauma
 - Pregnancy
 - Medication changes (e.g., rapid tapering of steroids)
 
 - Difficult to distinguish from cholinergic crisis resulting from excessive doses of acetylcholinesterase (AChE) inhibitors:
- Cholinergic crisis may also include muscarinic effects such as sweating, lacrimation, salivation, and GI hyperactivity in addition to weakness
 - Cholinergic crisis due to therapeutic AChE inhibitor use is rare, typically at very high doses
 
 
 
Epidemiology
Epidemiology
- Pediatric MG is rare and distinct:
- Congenital MG: Genetic defect
 - Juvenile MG: Autoimmune disorder
 - Transient neonatal MG: Postdelivery complication from placental transfer of maternal antibodies
 
 - Adult MG has bimodal distribution:
- First peak in second and third decades affecting mostly women
 - Second peak in sixth and seventh decades affecting men
 
 - Patients with MG may have other autoimmune conditions (e.g., lupus, rheumatoid arthritis, Graves)
 
Etiology
Etiology
- Antibody-mediated attack on nicotinic acetylcholine receptors on the postsynaptic membrane of the neuromuscular junction
 - Up to 20% of patients may be acetylcholine receptor antibody (AChR Ab) negative:
- Antibodies against other postsynaptic proteins (e.g., muscle-specific receptor tyrosine kinase, MuSK) may be involved
 
 - Many medications may worsen myasthenic weakness:
- Aminoglycosides, macrolides, quinolones, antimalarials
 - Local anesthetics
 - Antidysrhythmics (propafenone, quinidine, procainamide)
 - β-blockers, calcium-channel blockers
 - Anticonvulsants (phenytoin, carbamazepine)
 - Antipsychotics (phenothiazine, atypicals)
 - Neuromuscular blocking agents
 - Statins
 - Iodine-containing radiocontrast
 
 - Penicillamine can induce anti-AChR antibody production
 
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.